{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:20:55Z","timestamp":1790220055075,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Unitaid","award":["SPHQ15-LOA-045"],"award-info":[{"award-number":["SPHQ15-LOA-045"]}]},{"DOI":"10.13039\/100008196","name":"M\u00e9decins Sans Fronti\u00e8res","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Partners In Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment for fluoroquinolone-resistant multidrug-resistant\/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline and delamanid, and repurposed drugs clofazimine and linezolid, show great promise for combination in shorter, less-toxic, and effective regimens. To date, there has been no randomized, internally and concurrently controlled trial of a shorter, all-oral regimen comprising these newer and repurposed drugs sufficiently powered to produce results for pre-XDR TB patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>endTB-Q is a phase III, multi-country, randomized, controlled, parallel, open-label clinical trial evaluating the efficacy and safety of a treatment strategy for patients with pre-XDR TB. Study participants are randomized 2:1 to experimental or control arms, respectively. The experimental arm contains bedaquiline, linezolid, clofazimine, and delamanid. The control comprises the contemporaneous WHO standard of care for pre-XDR TB. Experimental arm duration is determined by a composite of smear microscopy and chest radiographic imaging at baseline and re-evaluated at 6\u00a0months using sputum culture results: participants with less extensive disease receive 6\u00a0months and participants with more extensive disease receive 9\u00a0months of treatment. Randomization is stratified by country and by participant extent-of-TB-disease phenotype defined according to screening\/baseline characteristics. Study participation lasts up to 104\u00a0weeks post randomization. The primary objective is to assess whether the efficacy of experimental regimens at 73\u00a0weeks is non-inferior to that of the control. A sample size of 324 participants across 2 arms affords at least 80% power to show the non-inferiority, with a one-sided alpha of 0.025 and a non-inferiority margin of 12%, against the control in both modified intention-to-treat and per-protocol populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This internally controlled study of shortened treatment for pre-XDR TB will provide urgently needed data and evidence for clinical and policy decision-making around the treatment of pre-XDR TB with a four-drug, all-oral, shortened regimen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.Gov NCT03896685. Registered on 1 April 2018; the record was last updated for study protocol version 4.3 on 17 March 2023.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07701-6","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:01:41Z","timestamp":1701327701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial"],"prefix":"10.1186","volume":"24","author":[{"given":"S. B.","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tamirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Khazhidinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Atger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bekhit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bektasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Berikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Caboclo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cloez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Coit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Coutisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Dakenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Delifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Demaisons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dos Santos Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ducher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ferlazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gouillou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lachenal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. N.","family":"LaHood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mazmanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moschioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Osso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Oyewusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"P\u00e2quet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Thuong Huu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rupasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Salahuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sanchez Garavito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. J.","family":"Seung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. E.","family":"Vel\u00e1squez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Varaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J.","family":"Yuya-Septoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. D.","family":"Mitnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Guglielmetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"7701_CR1","volume-title":"Global tuberculosis report 2018","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organ; 2018. WHO\/CDS\/TB\/2018.20."},{"key":"7701_CR2","unstructured":"WHO. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020. Geneva: World Health Organization CC BY-NC-SA 30 IGO; 2021."},{"issue":"10","key":"7701_CR3","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","volume":"16","author":"M Zignol","year":"2016","unstructured":"Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185\u201392.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"7701_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","volume":"9","author":"EW Orenstein","year":"2009","unstructured":"Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"7701_CR5","doi-asserted-by":"publisher","first-page":"e6914","DOI":"10.1371\/journal.pone.0006914","volume":"4","author":"J Johnston","year":"2009","unstructured":"Johnston J, Shahidi N, Sadatsafavi M, Fitzgerald J. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE. 2009;4(9):e6914.","journal-title":"PLoS ONE"},{"issue":"5","key":"7701_CR6","first-page":"684","volume":"9","author":"SSD Ahuja","year":"2012","unstructured":"Ahuja SSD, Avendano M, Banerjee RM, et al. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Med. 2012;9(5):684\u201392.","journal-title":"PLoS Med."},{"issue":"1","key":"7701_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09031936.00134712","volume":"42","author":"D Falzon","year":"2012","unstructured":"Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2012;42(1):156\u201368.","journal-title":"Eur Respir J"},{"issue":"1","key":"7701_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1164\/rccm.200911-1656OC","volume":"182","author":"DH Kim","year":"2010","unstructured":"Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, et al. Treatment Outcomes and Survival Based on Drug Resistance Patterns in Multidrug-resistant Tuberculosis. Am J Respir Crit Care Med. 2010;182(1):113\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"7701_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5588\/ijtld.15.0962","volume":"20","author":"M Bonnet","year":"2016","unstructured":"Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis. 2016;20(2):177\u201386.","journal-title":"Int J Tuberc Lung Dis"},{"key":"7701_CR10","unstructured":"WHO treatment guidelines for drug-resistant tuberculosis, 2016 update [Internet]. [cited 2023 Feb 11]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241549639."},{"key":"7701_CR11","unstructured":"Rapid \u0441ommunication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (\u200eMDR\/RR-TB). 2018. [cited 2023 Feb 11]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/WHO-CDS-TB-2018.18."},{"issue":"8","key":"7701_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, de Los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. N Engl J Med. 2014;371(8):723\u201332.","journal-title":"N Engl J Med."},{"key":"7701_CR13","doi-asserted-by":"crossref","unstructured":"Gler et al. - 2012 - Delamanid for multidrug-resistant pulmonary tuberculosis.pdf.","DOI":"10.1056\/NEJMoa1112433"},{"issue":"9","key":"7701_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","volume":"6","author":"K Schnippel","year":"2018","unstructured":"Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699\u2013706.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"7701_CR15","doi-asserted-by":"publisher","first-page":"1800544","DOI":"10.1183\/13993003.00544-2018","volume":"51","author":"O Olayanju","year":"2018","unstructured":"Olayanju O, Limberis J, Esmail A, Oelofse S, Gina P, Pietersen E, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J. 2018;51(5):1800544.","journal-title":"Eur Respir J"},{"key":"7701_CR16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201801-0019LE","author":"M Bastard","year":"2018","unstructured":"Bastard M, Guglielmetti L, Huerga H, Hayrapetyan A, Khachatryan N, Yegiazaryan L, et al. Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant MDR-TB: How Much Better Are They? Am J Respir Crit Care Med. 2018. https:\/\/doi.org\/10.1164\/rccm.201801-0019LE.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"7701_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, de Los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. N Engl J Med. 2014;371(8):723\u201332.","journal-title":"N Engl J Med"},{"issue":"23","key":"7701_CR18","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"MT Gler","year":"2012","unstructured":"Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151\u201360.","journal-title":"N Engl J Med."},{"issue":"11","key":"7701_CR19","first-page":"1382","volume":"8","author":"E Nathanson","year":"2004","unstructured":"Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8(11):1382\u20134.","journal-title":"Int J Tuberc Lung Dis."},{"key":"7701_CR20","doi-asserted-by":"crossref","unstructured":"Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, et al. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis. Am J Ther. 2016;23(2):e521\u2013530.","DOI":"10.1097\/01.mjt.0000433951.09030.5a"},{"issue":"2","key":"7701_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.5588\/ijtld.13.0369","volume":"18","author":"E Sanchez-Padilla","year":"2014","unstructured":"Sanchez-Padilla E, Marquer C, Kalon S, Qayyum S, Hayrapetyan A, Varaine F, et al. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: A quantitative and qualitative study. Int J Tuberc Lung Dis. 2014;18(2):160\u20137.","journal-title":"Int J Tuberc Lung Dis."},{"key":"7701_CR22","doi-asserted-by":"crossref","unstructured":"Shean K, Streicher E, Pieterson E, Symons G, van Zyl Smit R, Theron G, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One. 2013;8(5):e63057.","DOI":"10.1371\/journal.pone.0063057"},{"issue":"3","key":"7701_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa1604544","volume":"376","author":"NS Shah","year":"2017","unstructured":"Shah NS, Auld SC, Brust JCM, Mathema B, Ismail N, Moodley P, et al. Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. N Engl J Med. 2017;376(3):243\u201353.","journal-title":"N Engl J Med"},{"issue":"4","key":"7701_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","volume":"8","author":"Z Lan","year":"2020","unstructured":"Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8(4):383\u201394.","journal-title":"Lancet Respir Med."},{"key":"7701_CR25","unstructured":"WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva Licence: CC BY-NC-SA 30 IGO. 2022."},{"key":"7701_CR26","unstructured":"World Health Organization. WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update. Pre-final text. Geneva: World Health Organization; 2018."},{"key":"7701_CR27","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4, Module 4, [Internet]. 2020. [cited 2020 Dec 27]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558570\/."},{"key":"7701_CR28","unstructured":"Conradie F, Diacon AH, Howell P, Everitt D, Crook A, Mendel C, et al. Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid. The Hague: Union World Conference on Tuberculosis and Lung Health; 2018."},{"issue":"4","key":"7701_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5588\/ijtld.20.0513","volume":"25","author":"CD Tweed","year":"2021","unstructured":"Tweed CD, Wills GH, Crook AM, Amukoye E, Balanag V, Ban AYL, et al. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. Int J Tuberc Lung Dis. 2021;25(4):305\u201314.","journal-title":"Int J Tuberc Lung Dis."},{"key":"7701_CR30","doi-asserted-by":"crossref","unstructured":"Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, et al. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021;22(1):651.","DOI":"10.1186\/s13063-021-05491-3"},{"key":"7701_CR31","doi-asserted-by":"crossref","unstructured":"Bateson A, Ortiz Canseco J, McHugh TD, Witney AA, Feuerriegel S, Merker M, et al. Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. J Antimicrob Chemother. 2022;dkac070.","DOI":"10.1093\/jac\/dkac070"},{"key":"7701_CR32","doi-asserted-by":"crossref","unstructured":"Netikul T, Palittapongarnpim P, Thawornwattana Y, Plitphonganphim S. Estimation of the global burden of Mycobacterium tuberculosis lineage 1.\u00a0Infect Genet Evol. 2021;91:104802.","DOI":"10.1016\/j.meegid.2021.104802"},{"key":"7701_CR33","doi-asserted-by":"publisher","unstructured":"Padmapriyadarsini C, et al. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin Infect Dis 2022;76(3):e938\u2013e946. https:\/\/doi.org\/10.1093\/cid\/ciac528.","DOI":"10.1093\/cid\/ciac528"},{"key":"7701_CR34","doi-asserted-by":"crossref","unstructured":"Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331\u201343.","DOI":"10.1056\/NEJMoa2117166"},{"key":"7701_CR35","doi-asserted-by":"crossref","unstructured":"Rich ML, Khan U, Zeng C. Outcomes of WHO-conforming longer all-oral multidrug-resistant tuberculosis regimens and analysis implications. Int J Tuberc Lung Dis. 2023. In press.","DOI":"10.5588\/ijtld.22.0613"},{"issue":"11","key":"7701_CR36","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","volume":"24","author":"MZ Imperial","year":"2018","unstructured":"Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708\u201315.","journal-title":"Nat Med."},{"key":"7701_CR37","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03828201."},{"issue":"2","key":"7701_CR38","first-page":"241","volume":"14","author":"AJ Nunn","year":"2010","unstructured":"Nunn AJ, Phillips P, Mitchison D. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis. 2010;14(2):241\u20132.","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07701-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07701-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07701-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:03:13Z","timestamp":1701327793000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07701-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7701"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07701-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the study protocol and informed consent materials was granted before the study start from the following IRBs: M\u00e9decins sans Fronti\u00e8res Ethics Review Board, Harvard Medical School Institutional Review Board, Interactive Research and Development Institutional Review Board, Institute of Tropical Medicine Institutional Review Board, and IRBs\/Ethics Committees in all countries in which the study is implemented. Any amendments to the protocol or consent materials are reviewed and approved by central IRBs (MSF, HMS) before they are submitted to local authorities and local IRBs for approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The endTB Consortium coordinated donations of delamanid (Otsuka Pharmaceutical) and bedaquiline (Janssen) to be used for treatment by some of the patients included in the endTB Observational Study.Authors report the following potential conflicts of interest: none other than the donations disclosed above.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"773"}}